InVenis Biotherapies offers IVB001, an off‑the‑shelf, cell‑free platelet secretome that delivers a broad mix of neuroprotective, anti‑inflammatory, antioxidant, and anti‑ferroptotic factors. The product is manufactured to remove pro‑inflammatory components, enabling chronic intravenous use without immunogenicity or tumorigenicity risks, and is positioned for partners developing therapies for ALS, Parkinson’s disease, and traumatic brain injury.
Funding
Funding not disclosed
Founders
Product
Problem
Neurodegenerative diseases such as ALS, Parkinson’s disease, and traumatic brain injury involve multiple, interrelated pathological processes—including mitochondrial dysfunction, oxidative stress, and neuroinflammation—making single‑target drugs largely ineffective. Patients lack therapies that can safely address this complex biology while being practical for chronic administration.
Solution
InVenis Biotherapies develops a cell‑free platelet secretome product, IVB001, that delivers a broad spectrum of neuroprotective, anti‑inflammatory, antioxidant, and anti‑ferroptotic factors in a single off‑the‑shelf formulation. The secretome is derived from allogenic clinical‑grade platelet concentrates and processed to remove pro‑inflammatory components, reducing the risk of central nervous system toxicity. By providing a multi‑targeted biologic that can be administered chronically without the immunogenicity or manufacturing challenges of cell‑based therapies, IVB001 aims to slow disease progression and promote neuronal repair across several neurodegenerative indications.
Target Audience
Primary customers are pharmaceutical and biotech companies, as well as academic research programs, developing therapies for ALS, Parkinson’s disease, and traumatic brain injury that require a multi‑targeted, safe biologic platform.
Features
- Cell‑free platelet secretome containing dozens of bioactive molecules (e.g., BDNF, PDGF, VEGF, SOD, GPX1, TGF‑β) that act on neuroprotection, anti‑inflammation, antioxidant, and synaptic plasticity pathways
- Proprietary manufacturing process that depletes pro‑neuroinflammatory factors such as fibrinogen and complement, minimizing CNS toxicity
- Pathogen‑free, allogenic product sourced from certified blood establishments, ensuring consistent quality and safety
- Off‑the‑shelf formulation suitable for chronic intravenous administration without the logistical complexity of live cell therapies
- Cell‑free platform avoids immunogenicity and tumorigenicity risks associated with cellular approaches